Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst. 1960;25:85–109.

CAS  PubMed  Google Scholar 

Bassan R, Rossi G, Pogliani EM, Di Bona E, Angelucci E, Cavattoni I, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol. 2010;28(22):3644–52.

Article  CAS  PubMed  Google Scholar 

Chiaretti S, Vitale A, Vignetti M, Piciocchi A, Fazi P, Elia L, et al. A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. Haematologica. 2016;101(12):1544–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yilmaz M, Kantarjian H, Ravandi-Kashani F, Short NJ, Jabbour E. Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives. Clin Adv Hematol Oncol. 2018;16(3):216–23.

PubMed  Google Scholar 

Soverini S, Bassan R, Lion T. Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. J Hematol Oncol. 2019;12(1):39.

Article  PubMed  PubMed Central  Google Scholar 

Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2007;110(2):727–34.

Article  CAS  PubMed  Google Scholar 

Sherbenou DW, Hantschel O, Turaga L, Kaupe I, Willis S, Bumm T, et al. Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia. Leukemia. 2008;22(6):1184–90.

Article  CAS  PubMed  Google Scholar 

Ide A, Tokunaga M, Yoshikawa S, Kondo A, Nishiura N, Inoue S, et al. Chronic myeloid leukemia with an in-frame exon 4 deletion in ABL1 with acute abdomen due to an intrapelvic bulky mass as the initial symptom. Rinsho Ketsueki. 2021;62(11):1615–22.

PubMed  Google Scholar 

Vaidya S, Vundinti BR, Shanmukhaiah C, Chakrabarti P, Ghosh K. Evolution of BCR/ABL gene mutation in CML is time dependent and dependent on the pressure exerted by tyrosine kinase inhibitor. PLoS ONE. 2015;10(1): e0114828.

Article  PubMed  PubMed Central  Google Scholar 

Gruber FX, Hjorth-Hansen H, Mikkola I, Stenke L, Johansen T. A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib. Leukemia. 2006;20(11):2057–60.

Article  CAS  PubMed  Google Scholar 

Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5(3):172–83.

Article  CAS  PubMed  Google Scholar 

Ma W, Kantarjian H, Yeh CH, Zhang ZJ, Cortes J, Albitar M. BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors. Acta Haematol. 2009;121(1):27–31.

Article  PubMed  PubMed Central  Google Scholar 

Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell. 2003;112(6):831–43.

Article  CAS  PubMed  Google Scholar 

O’Hare T, Zabriskie MS, Eide CA, Agarwal A, Adrian LT, You H, et al. The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Blood. 2011;118(19):5250–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yuda J, Miyamoto T, Odawara J, Ohkawa Y, Semba Y, Hayashi M, et al. Persistent detection of alternatively spliced BCR-ABL variant results in a failure to achieve deep molecular response. Cancer Sci. 2017;108(11):2204–12.

Article  CAS  PubMed  PubMed Central  Google Scholar